Quantum BioPharma is up 7.7% in pre-market at $3.52, versus $3.27 at the October 5 close; the reason is unclear. - No October 6 company announcement surfaced; no specific catalyst was verified, and pre-market volume was unverified. - On October 2, the company received final reports for two Lucid-MS studies supporting its Phase 2 program; sources do not link this news to the move. - Major U.S. indices were modestly positive, none up more than 0.5%, offering no clear explanation.